Trial Profile
A phase I/II, open-label, AUC-controlled study to determine the pharmacokinetics, safety, tolerability, and antiviral activity of DMP 266 (efavirenz) in combination with nelfinavir in children
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Nelfinavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2016 Results assessing pharmacokinetics of four trials published in the Antimicrobial Agents and Chemotherapy
- 20 Oct 2005 New trial record.